GlassScriptPhysician profile
Jennifer Durham
NPI 1457399206
$2,321.38
in general payments reported to CMS, 2019-2025
22 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $441 · 2023: $319 · 2024: $693 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $301.05 | 2021-2025 | Wainua, Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $298.34 | 2022-2025 | |
| Pfizer INC. | $251.41 | 2022-2025 | |
| Amgen INC. | $185.38 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $163.42 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $150.38 | 2022 | |
| Novo Nordisk INC | $131.33 | 2022-2025 | Ozempic, Wegovy |
| Abbott Laboratories | $127.33 | 2025 | Cardiomems |
| Janssen Pharmaceuticals, INC | $106.84 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $96.71 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $96.32 | 2021-2024 | Nexletol |
| Boston Scientific Corporation | $93.34 | 2023-2025 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.07 | 2022-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $46.56 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $39.64 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $26.93 | 2024 | |
| Recor Medical INC | $26.85 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cvrx, INC. | $23.49 | 2024 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $22.53 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $21.61 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2025 | |
| Heartflow, INC. | $17.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Durham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.